Begin main content

Omalizumab (Drug Plan Submission)

Last Updated: October 6, 2015
Result type: Reports
Project Number: SR0457-000
Product Line: Common Drug Review

Generic Name: Omalizumab (Drug Plan Submission)

Brand Name: Xolair

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Asthma, severe persistent

Submission Type: Resubmission 2

Project Status: Complete

Date Recommendation Issued: May 18, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions